Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

References

• Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med. 2015;373(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62(23):6997–7000.
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–2147.
   PubMed Web of Science ®Google Scholar
• Krauthhammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet. 2015;47:996–1002.
   PubMed Web of Science ®Google Scholar
• Padua RA, Barrass N, Currie GA. A novel-transforming gene in a human malignant melanoma cell line. Nature. 1984;311(5987):671–673.
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signaling cascades. Nature. 2001;410(6824):37–40.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF. Nature. 2010;64(7287):427–430.
   Web of Science ®Google Scholar
• Wong DJ, Ribas A. Targeted therapy for melanoma. Cancer Treat Res. 2016;167:251–262.
   PubMedGoogle Scholar
• Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251–263.
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581–586.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358–364.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;12(367):107–114.
   Web of Science ®Google Scholar
• Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):782–789.
   PubMed Web of Science ®Google Scholar
• Von Euw E, Atefi M, Attar N, et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012;11:22.
   PubMed Web of Science ®Google Scholar
• Atefi M, Von Euw E, Attar NET, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Plos One. 2011;6(12):e28973.
   PubMed Web of Science ®Google Scholar
• Dummer R, Schadendorf D, Ascierto PA, et al. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J Clin Oncol. 2016;34(Suppl):abstr 9500.
   Google Scholar
• Wagle N, Van Allen EM, Treacy DJ, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014;4:61–68.
   PubMed Web of Science ®Google Scholar
• Moriceau G, Hugo W, Hong A, et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015;27:240–256.
   PubMed Web of Science ®Google Scholar
• Posch C, Moslehi H, Feeney L, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013;110(10):4015–4020.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–977.
   PubMed Web of Science ®Google Scholar
• Shi H, Hong A, Kong X, et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014;4(1):69–79.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature. 2011;480(7377):387–390.
   PubMed Web of Science ®Google Scholar
• Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res. 2014;20(7):1965–1977.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl J Med. 2012;367:1694–1703.
   PubMed Web of Science ®Google Scholar
• Flaherty K, Davies MA, Grob JJ, et al. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. J Clin Oncol. 2016;34(Suppl):abstr 9502.
   Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451.
   PubMed Web of Science ®Google Scholar
• Su F, Viros A, Milagre A, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–215.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389–1398.
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib and trametinib vs vemurafenib as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Journal of Cancer. 2015;51(Suppl 3):S663 Abstract 3301.
   Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–39.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF (V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–1260.
   PubMed Web of Science ®Google Scholar
• Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15:954–965.
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. New Engl J Med. 2014;371:1867–1876.
   PubMed Web of Science ®Google Scholar
• Akinleye A, Furgan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:27.
   PubMed Web of Science ®Google Scholar
• Thumar J, Shahbazian D, Aziz SA, et al. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer. 2014;13:45.
   PubMed Web of Science ®Google Scholar
• wong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18(10):1503–1510.
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340–4346.
   PubMed Web of Science ®Google Scholar
• Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004;23(22):3999–4006.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Corless CL, Giobbies-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182–3190.
   PubMed Web of Science ®Google Scholar
• Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904–2909.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. Jama. 2011;305(22):2327–2334.
   PubMed Web of Science ®Google Scholar
• Todd JR, Becker TM, Kefford RF, et al. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. Pigment Cell Melanoma Res. 2013;26(4):518–526.
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Speith K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the dermatologic cooperative oncology group. J Clin Oncol. 2005;23:9001–9007.
   PubMed Web of Science ®Google Scholar
• Danson S, Lorigan P, Arance A, et al. Randomized phase II study of temozolomide given every 8 hours or daily with either INF alfa 2b or thalidomide in metastatic malignant melanoma. J Clin Oncol. 2003;21:2551–2557.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze M, Dutcher JP. High-dose recombinat interleukin 2 therapy for patients with metastatic melanoma. J Clin Oncol. 1999;12(7):2105–2116.
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Lee P, Wallace E, Marlow A, et al. Preclinical development of ARRY-162, a potent and selective MEK 1/2 inhibitor. Cancer Res. 2010;70:2515.
   Web of Science ®Google Scholar
• Winski S, Anderson D, Bouhana K, et al. MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations. Proceedings of the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; Berlin, Germany; 2010 Nov 16–19.
   Google Scholar
• Von Euw EM, Hong-Mei R, O’Brien N, et al. Abstract 2437: MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status. Proceedings: AACR 104th Annual Meeting 2013; 2013 Apr 6-10; Washington, DC
   Google Scholar
• Finn RS, Javl MM, Tan BR, et al. A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. J Clin Oncol. 2012;30(Suppl4): abstr 220.
   Web of Science ®Google Scholar
• Watanabe K, Otsu S, Hirashima Y, et al. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(6):1157–1164.
   PubMed Web of Science ®Google Scholar
• Cho MT, Lim D, Synold T, et al. A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer. J Clin Oncol. 2016;34(suppl 4S):abstr 679.
   Google Scholar
• Cao J, Heijkants RC, Jochemsen AG, et al. Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy. Oncotarget. 2016;22:5.
   Google Scholar
• Bendell J, Papadopoulos K, Jones S, et al. Phase 1 dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2011: p. abstr B243.
   Google Scholar
• Van Dijk EH, Van Herpen CM, Marinkkovic M, et al. Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology. 2015;122(9):1907–1916.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14(3):249–256.
   PubMed Web of Science ®Google Scholar
• Urner-Bloc U, Urner M, Jaberg-Bentele N, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014;25(7):1437–1441.
   PubMed Web of Science ®Google Scholar
• Kefford R, Miller WH Jr, Tan DS-W, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. J Clin Oncol. 2013;31(suppl):abstr 9029.
   Google Scholar
• Li Z, Jiang K, Zhu X, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016;370(2):332–344.
   PubMed Web of Science ®Google Scholar
• Stuart DD, Li N, Poon DJ, et al. Abstract 3790: preclinical profile of LGX818: A potent and selective RAF kinase inhibitor. Cancer Res. 2012;72(8 Suppl):abstr 3790.
   Web of Science ®Google Scholar
• Adelmann C, Ching G, Du L, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016;7(21):30453–30460.
   PubMed Web of Science ®Google Scholar
• Dummer R, Robert C, Nyakas M, et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. J Clin Oncol. 2013;31(Suppl):abstr 9028.
   Google Scholar
• Gomez-Roca CA, Delord J, Robert C, et al. Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (mCRC): results of dose expansion in an phase I trial. Ann Oncol. 2014;25(Suppl4):iv167–iv209.
   Google Scholar
• Sosman JA, Kittaneh M, Martijn PJK, et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. J Clin Oncol. 2014;32(5s):abstr 9009.
   Google Scholar
• Van Herpen C, Postow MA, Carlino MS, et al. A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma. Eur J Cancer. 2015;51(Supplement 3):S663.
   Google Scholar
• Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19:5320–5328.
   PubMed Web of Science ®Google Scholar
• Sullivan RY, Weber JS, Patel SP, et al. A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. J Clin Oncol. 2015;33(suppl):abstr 9007.
   Google Scholar
• Dummer R, Sandhu S, Hassel JC, et al. LOGIC2: phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. Presented at: 2015 European Cancer Congress; September 25-29; Vienna, Austria. Abstract 3310.
   Google Scholar
• Dummer R, Asierto PA, Gogas HJ, et al. Results of COLUMBUS part 1: a phase 3 trial os encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma. Presented at 2016 Society for Melanoma Research.
   Google Scholar
• Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–1366.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Robert L, Moreo H, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014;32(21):2248–2254.
   PubMed Web of Science ®Google Scholar
• Atefi M, Avramis E, Lassen A, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014;20(13):3446–3457.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhou J, Giobbie-Hurder A. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clinc Cancer Res. 2013;19(3):598–609.
   PubMed Web of Science ®Google Scholar
• Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. Plos One. 2009;4(9):e7258.
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–344.
   PubMed Web of Science ®Google Scholar
• Soria JC, Massard C, Magnes N, et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer. 2009;45(13):2333–2341.
   PubMed Web of Science ®Google Scholar
• Prosvicova J, Lukesova S, Kopecky J, et al. Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(4):695–697.
   PubMed Web of Science ®Google Scholar
• Kassim SY AB Science 6/16/15. 2015 [cited 2016 Oct. 10]; Available from: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2015/ucm453979.htm.
   Google Scholar
• Rose AA, Annis MG, Frederick DT, et al. MAPK pathway inhibitors sensitize BRAF-mutant melanoma to an antibody-drug conjugate targeting GPMNB. Clin Can Res. 2016;22(24):6088–6098.
   PubMed Web of Science ®Google Scholar
• Krepler C, Xiao M, Sproesser K. Personalized Preclinical Trials in BRAF inhibitor–resistant patient-derived xenograft models identify second-line combination therapies. Clin Can Res. 2016;22(7):1603–1610.
   PubMed Web of Science ®Google Scholar
• Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015;21(7):1639–1651.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF (V600E) melanoma. Sci Transl Med. 2015;7(279):279ra41.
   PubMed Web of Science ®Google Scholar